Unnatural Products Announces Strategic Oral Macrocyclic Peptide Collaboration with argenx

This collaboration will leverage UNP's proprietary drug discovery platform to generate potent, selective, and orally available macrocyclic peptides against multiple targets of interest identified by arginine. Under the terms of the agreement, UNP will conduct research and development up to Phase I.ND-enablingResearchArgenx will have the exclusive option to develop and commercialize products targeting multiple indications.

Under the terms of the agreement, UNP will receive upfront, near-term payments and R&D funding. UNP is also eligible to receive up to approximately $1.5 billion in potential research, development, regulatory, and commercial milestones and option payments, as well as tiered royalties on net sales. Additionally, argenxWill make an equity investment in UNP.

Dr. Cameron Pye, CEO and co-founder of Unnatural Products, stated: "Macrocyclic peptides are pioneering a new form of medicine that combines the best attributes of biologics and small molecules with drug targets once thought unreachable. Argenx has built a world-class engine for immunology innovation, and we are thrilled to collaborate with them to advance novel macrocyclic peptide therapies for patients with immune system disorders."

UNP's platform combines AI-guided compound design, large-scale parallel synthesis, and direct biological screening to rapidly generate drug-like macrocycles with antibody-like specificity, targeting challenging targets. UNP is building an oral drug pipeline for oncology, immunology, and rare diseases.

AboutUnnatural Products

Unnatural Products (UNP) is a company focused on biotechnology innovation, dedicated to developing groundbreaking molecular targeted therapies through the deep integration of artificial intelligence and chemical synthesis technology.